Pressed for time? Here's the medtech news you need most, in one minute or less.

The structural heart leader expects to see double-digit growth in transcatheter aortic valve replacement (TAVR) sales next year.

This marks the sixth FDA clearance the NY-based company has received.

Study findings point out the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority for the primary hierarchical efficacy endpoint.

These are the companies in the private sector that medtech analysts have called attention to in 2020.

Results from the SCOPE II trial were presented at TCT Connect and showed the Acurate Neo failed to demonstrate non-inferiority when compared to Medtronic’s CoreValve Evolut.

The Chicago, IL-based company has received FDA clearance for the Vivid Ultra Edition, an AI-powered cardiovascular ultrasound system.

Boston Scientific has a plan to tackle systemic racism in healthcare, and to stop the "Black amputation epidemic."